Drug intelligence / Profile preview

ADC-02520849

Development stage: Preclinical
Lead developer: Curis
Modality: Small Molecules
Administration: Oral, Intracerebral

Overview

ADC-02520849 is a small molecule opioid receptor ligand developed for research and potential therapeutic application in neurological disorders such as Parkinson's disease. It acts as a selective antagonist at the μ opioid receptor (MOR), with high affinity and selectivity over δ and κ opioid receptors. In preclinical models, ADC-02520849 has been explored for its ability to modulate L-DOPA-induced dyskinesia by blocking μ opioid receptor signaling. The compound was developed by Curis and shows potential for oral and intracerebral administration in primate models of neurodegenerative disease[3].

Brand names: ADC-02520849ADC02520849ADC 02520849
Other names: ADC-02520849ADC02520849ADC 02520849

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on ADC-02520849.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADC-02520849.

Explore the full profile